Metsera Secures $215 Million to Advance Weight Loss Drug Pipeline
Metsera raised $215 million in a Series B funding round to advance its portfolio of GLP-1 receptor agonists for weight loss, bringing its total funding to over $500 million.
FDA Approves Amneal's Extended-Release Pyridostigmine Bromide Tablets for Nerve Agent Pretreatment
The FDA has approved Amneal's pyridostigmine bromide ER tablets (105 mg) for pretreatment against soman nerve agent poisoning in adults.
FTC Orange Book Patent Challenge Initiative Shows Mixed Results as Most Listings Remain in Force
The Federal Trade Commission has challenged over 400 pharmaceutical patent listings in the FDA's Orange Book since September 2023, claiming many are improperly listed to delay generic competition.
© Copyright 2025. All Rights Reserved by MedPath